<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>Emerging market opportunities include developing IGF-1R-targeted therapies for thyroid eye disease, leveraging prior success with Tepezza. In oncology, focus on biomarker-driven patient stratification and combination treatments may overcome previous challenges, presenting renewed therapeutic potential.Dublin, May 14, 2026 (GLOBE NEWSWIRE) -- The <a href="https://www.researchandmarkets.com/reports/6179375/pipeline-igf-1r-igf-1-targeted-immunotherapy?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=3kfjgw&amp;utm_campaign=2252510+-+IGF-1R-+and+IGF-1+Targeted+Immunotherapy+Pipeline+Competitor+Analysis+Report+2026%3a+Active+R%26D+Programs+by+R%26D+Phase+and+Profile+of+Targeted+Therapies+by+Drug+Modality&amp;utm_exec=chdomspi" rel="nofollow" target="_blank" title="Pipeline of IGF-1R- and IGF-1 Targeted Immunotherapy">"Pipeline of IGF-1R- and IGF-1 Targeted Immunotherapy"</a> report has been added to ResearchAndMarkets.com's offering. This competitive intelligence report about IGF-1(R)-Targeted Immunotherapies provides an up-to-date competitor evaluation in the field of product candidates in research and development targeting IGF-1R or its ligand IGF-1. This report will be prepared on demand within one working day upon order placement. The report lists active IGF-1(R)-targeted R&amp;D programs by R&amp;D phase in a tabular format and describes in brief the profile of IGF-1(R)-targeted therapies by drug modality. Insulin-like growth factor- receptor (IGF-1R) is a transmembrane tyrosine kinase receptor that plays a role in development, metabolism, and immune regulation, and is overexpressed in orbital fibroblasts (OFs), B, and T cells of thyroid ophthalmopathy in Graves' disease. Blocking IGF-1(R) signalling reduces the expression of downstream inflammatory factors, thereby inhibiting the synthesis of hyaluronic acid and other glycosaminoglycans caused by OFs activation, as well as related inflammatory reactions including tissue congestion and edema; inhibit adipocyte cellularization of OFs, thereby reducing the disease activity of patients with active thyroid ophthalmopathy and improving proptosis, diplopia, ocular congestion and edema and other symptoms and signs. Clinical and commercial validation of IGF-1R as a target for treatment of thyroid eye disease (TED) is highlighted by 2024 global sales of nearly US$ 1.9 bln of the first approved anti-IGF-1R therapeutic antibody Tepezza. IGF-1R has also emerged as a critical target in oncology due to its pivotal role in tumor growth, progression, and therapeutic resistance. IGF-1R was among the most intensively pursued kinase targets in oncology. However, even after a slew of small-molecule and antibody therapeutics reached clinical trials for a range of solid tumors, the initial promise remains unfulfilled. Mechanisms of resistance to, and toxicities resulting from, IGF-1R-targeted drugs are well-catalogued, and there is general appreciation of the fact that a lack of biomarker-based patient stratification was a limitation of previous clinical trials. But no next-generation therapeutic strategies have yet successfully exploited this understanding in the clinic. Currently there is emerging interest in re-visiting IGF-1R targeted therapeutics in combination-treatment protocols with predictive biomarker-driven patient-stratification. For more information about this report visit <a href="https://www.researchandmarkets.com/reports/6179375/pipeline-igf-1r-igf-1-targeted-immunotherapy?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=3kfjgw&amp;utm_campaign=2252510+-+IGF-1R-+and+IGF-1+Targeted+Immunotherapy+Pipeline+Competitor+Analysis+Report+2026%3a+Active+R%26D+Programs+by+R%26D+Phase+and+Profile+of+Targeted+Therapies+by+Drug+Modality&amp;utm_exec=chdomspi" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/bcrwiu</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/NjEzMDI3NzYtMTNmZC00NjJhLWE3YjItMzEyOTRiOGE1NGViLTEwMjY3MzctMjAyNi0wNS0xNC1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Competitor Analysis Report 2026: Active R&D Programs by R&D Phase and Profile of Targeted Therapies by Drug Modality

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn